Biogen licenses Mitsubishi's autoimmune candidate

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) granted Biogen Inc. (NASDAQ:BIIB) an exclusive license to develop and commercialize MT-1303 worldwide, excluding Asian territories.

Mitsubishi will receive $60 million up front and is eligible for $484 million in milestones, plus royalties. ...